Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis.

Authors: Sallinen, S L  Sallinen, P K  Kononen, J T  Syrjäkoski, K M  Nupponen, N N  Rantala, I S  Helén, P T  Helin, H J  Haapasalo, H K 
Citation: Sallinen SL, etal., J Pathol. 1999 Jul;188(3):289-93. doi: 10.1002/(SICI)1096-9896(199907)188:3<289::AID-PATH351>3.0.CO;2-X.
Pubmed: (View Article at PubMed) PMID:10419598
DOI: Full-text: DOI:10.1002/(SICI)1096-9896(199907)188:3<289::AID-PATH351>3.0.CO;2-X

An important positive regulator of the cell cycle, cyclin D1, is often amplified and overexpressed in malignancies. Cyclin D1 aberrations were analysed in grade II-IV astrocytomas by fluorescence in situ hybridization (FISH), mRNA in situ hybridization and immunohistochemistry. Proliferation activity was determined by Ki-67(MIB-1) immunolabelling and mitotic counting. High cyclin D1 expression was observed in grade IV astrocytomas (grades II-III versus grade IV; mRNA expression: p<0.001; immunoexpression: p=0.013), and correlated with poor patient survival (p<0.001, n=46). Upregulated cyclin D1 expression was also closely associated with poor patient prognosis in grade II-III astrocytomas (p<0.001, n=30). Cyclin D1 gene was not found to be amplified (n=7). Cell proliferation activity was significantly increased in tumours exhibiting high cyclin D1 mRNA levels (Ki-67(MIB-1): p<0.001; mitotic count: p<0.001) and high cyclin D1 protein expression (Ki-67(MIB-1): p=0.002; mitotic count: p=0.012). These results indicate that increased production of cyclin D1 is closely associated with high cell proliferation activity and aggressive behaviour in diffusely infiltrating astrocytomas.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 13681931
Created: 2018-07-12
Species: All species
Last Modified: 2018-07-12
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.